Acceptance of adverse event risk is low in RA

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1387, 2003-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Leflunomide: no increase in hepatic adverse event risk?

By  

Reactions Weekly, Vol. 1, Iss. 1016, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Antimicrobials and the Risk of Torsades de Pointes: The Contribution from Data Mining of the US FDA Adverse Event Reporting System

By Poluzzi Elisabetta  

Drug Safety, Vol. 33, Iss. 4, 2010-04 ,pp. : 303-314

Adis International

Access to resources Recommend Favorite

Safety and adverse event profile of duloxetine

By Wernicke Joachim F   Gahimer James   Yalcin Ilker   Wulster-Radcliffe Meghan   Viktrup Lars  

Expert Opinion on Drug Safety, Vol. 4, Iss. 6, 2005-11 ,pp. : 987-993

Informa Healthcare

Access to resources Recommend Favorite

Adverse-Event Profile of Crataegus Spp.: A Systematic Review

By Daniele Claudia  

Drug Safety, Vol. 29, Iss. 6, 2006-01 ,pp. : 523-535

Adis International

Access to resources Recommend Favorite

Guidelines for Submitting Adverse Event Reports for Publication

By Kelly William N.  

Drug Safety, Vol. 30, Iss. 5, 2007-01 ,pp. : 367-373

Adis International

Access to resources Recommend Favorite